Cancer Test Startup Aims for $5B Splash

Heard the buzz? Caris Life Sciences, the company behind those high-tech cancer tests, is about to hit the stock market with a $5.3 billion price tag. If you’ve ever wondered who’s making those blood tests your doctor orders, it’s companies like Caris—and now you could own a piece. With IPOs making a comeback, Caris is betting big that more people want smarter, AI-powered cancer diagnostics. Will their tech outshine the competition? Time (and investors) will tell! #IPO #CancerDiagnostics #Investing101 #Business